Clinical Study of 68Ga-LNC1007 Injection PET/CT

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

May 27, 2025

Study Completion Date

May 27, 2025

Conditions
Healthy VolunteersCancer Patients
Interventions
DRUG

68Ga-LNC1007 Injection

The participant will receive a single intravenous injection with 0.05 mCi/kg (according to the participants' body weight) 68Ga-LNC1007 Injection on the scan bed. The final dose of the drug is allowed to fluctuate within the 20% range, but not below 3 mCi. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.

Trial Locations (1)

Unknown

Clinical Imaging Research Centre (CIRC) ;National University of Singapore., Singapore

All Listed Sponsors
lead

Yantai LNC Biotechnology Singapore PTE. LTD.

INDUSTRY

NCT06463782 - Clinical Study of 68Ga-LNC1007 Injection PET/CT | Biotech Hunter | Biotech Hunter